XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
27.13
+2.02 (8.04%)
Dec 20, 2024, 4:00 PM EST - Market closed
XOMA Royalty Revenue
XOMA Royalty had revenue of $7.20M in the quarter ending September 30, 2024, with 767.11% growth. This brings the company's revenue in the last twelve months to $21.61M, up 389.82% year-over-year. In the year 2023, XOMA Royalty had annual revenue of $4.76M, down -21.06%.
Revenue (ttm)
$21.61M
Revenue Growth
+389.82%
P/S Ratio
14.57
Revenue / Employee
$1,662,000
Employees
13
Market Cap
319.67M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
Dec 31, 2019 | 18.37M | 13.07M | 246.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OraSure Technologies | 224.26M |
Canopy Growth | 207.63M |
Cerus | 176.23M |
Rigel Pharmaceuticals | 157.37M |
AVITA Medical | 60.04M |
CVRx, Inc. | 47.26M |
Aclaris Therapeutics | 27.08M |
Silence Therapeutics | 21.77M |
XOMA News
- 2 days ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 6 weeks ago - XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities - GlobeNewsWire
- 2 months ago - XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience - GlobeNewsWire
- 2 months ago - Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash - Business Wire
- 2 months ago - XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties - Seeking Alpha
- 2 months ago - I Am Banking On The Silver Tsunami With Big Dividends - Seeking Alpha
- 2 months ago - XOMA Stock Dips Amidst Biotech Sector Decline - GuruFocus
- 3 months ago - Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) - GlobeNewsWire